Harrison, Stephen; Dubourg, Julie; Megnien, Sophie Jeannin et al.
Glycated hemoglobin as an independent predictor of hepatocyte ballooning in non-alcoholic steatohepatitis: combined data from multiple clinical trials including more than 5000 patients (in collaboration with NAIL-NIT consortium)JOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S619-S620
Harrison, Stephen A.; Dubourg, Julie; Jeannin, Sophie et al.
GLYCEMIC CONTROL IMPACTS FIB-4 PERFORMANCE TO PREDICT ADVANCED FIBROSIS AND IS INDEPENDENTLY ASSOCIATED WITH THE PRESENCE OF HEPATOCYTE BALLOONING: COMBINED DATA FROM MULTIPLE THERAPEUTIC TRIALS INCLUDING MORE THAN 6,000 PATIENTS ( IN COLLABORATION WITH NAIL- NIT CONSORTIUM)HEPATOLOGY. Bd. 78. 2023 S. S802-S806
Gross, Sabrina; Bitzer, Michael; Bloedt, Susanne et al.
Guideline report of the S3 guideline diagnostics and therapy of hepatocellular carcinoma and biliary carcinomaZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 61. H. 04. 2023 S. E157-E171
Llovet, Josep M.; Kudo, Masatoshi; Merle, Philippe et al.
Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. 2023 S. 506-506
Elimova, Elena; Wyrwicz, Lucjan; Chen, Clara et al.
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/ gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 16. 2023
Moehler, Markus; Xiao, Hong; Blum, Steven I. et al.
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649JOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 35. 2023 S. 5388-+
Hsu, Chiun; Ducreux, Michel; Zhu, Andrew X. et al.
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus BevacizumabLIVER CANCER. Bd. 12. H. 1. 2023 S. 44-56
Schattenberg, Joern; Ren, Yayun; Tai, Dean et al.
Hepatic fat and liver volume reductions-impact on non-alcoholic steatohepatitis trials and potential solutions using concomitant fibrosis with ballooning with fibrosisJOURNAL OF HEPATOLOGY. Bd. 78. 2023 S. S824-S824
Zhang, Huai; Rios, Rafael S.; Boursier, Jerome et al.
Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry studyCHINESE MEDICAL JOURNAL. Bd. 136. H. 3. 2023 S. 341-350
Franck, Martin; John, Katharina; Al Aoua, Sherin et al.
Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patientsLIVER INTERNATIONAL. 2023